Table 3.

HRs and 95% CIs of PTEN expression to predict time to lethal prostate cancer in the HPFS (1986–2010) and PHS (1983–2010) Prostate Tumor Cohort

PTEN expressionNo. of lethal casesHRa (95% CI)HRb (95% CI)HRc (95% CI)
Percent staining
Per 10% decrease761.2 (1.0–1.3)1.2 (1.0–1.3)1.1 (0.93–1.2)
Q1—Lower242.4 (1.2–4.7)2.4 (1.2–4.7)1.6 (0.82–3.3)
Q2151.2 (0.59–2.7)1.2 (0.56–2.6)1.0 (0.44–2.1)
Q3221.7 (0.87–3.5)1.7 (0.87–3.5)1.6 (0.77–3.2)
Q4—higher15111
Ptrend0.040.040.33
Low percent (<32%)611.8 (0.98–3.2)1.7 (0.98–3.2)1.4 (0.76–2.6)
Multiplicative score
Per SD decrease761.4 (1.1–1.8)1.4 (1.1–1.8)1.2 (0.88–1.6)
Q1—lower242.6 (1.3–5.2)2.6 (1.3–5.2)1.8 (0.85–3.6)
Q2141.4 (0.62–3.0)1.3 (0.6–3.0)1.1 (0.48–2.5)
Q3252.3 (1.1–4.7)2.3 (1.1–4.7)2.0 (0.97–4.3)
Q4—higher13111
Ptrend0.030.030.27
Low score (<32.25)632.1 (1.1–3.9)2.1 (1.1–3.9)1.6 (0.86–3.1)

NOTE: Lethal prostate cancer is defined as fatal prostate cancer or distant metastasis.

  • aHRs adjusted for age at diagnosis and diagnosis era.

  • bHRs adjusted for age at diagnosis, diagnosis era, baseline BMI, and smoking status.

  • cHRs adjusted for age at diagnosis, diagnosis era, baseline BMI, smoking status, tumor stage, Gleason grade, and PSA at diagnosis.